6 ML RADIUM CHLORIDE RA-223 30 MCI/ML Injection [Xofigo]
Semantic Scholar uses AI to extract papers important to this topic.
Background and Objective: Radium-223 dichloride (Xofigo®) is a calcium mimetic agent approved for the treatment of castration… Expand Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10… Expand The integrity of the genome of eukaryotic cells is secured by complex signaling pathways, known as DNA damage response (DDR… Expand ZusammenfassungAlpharadin (223Radiumdichlorid/Xofigo®) ist ein seit November 2013 zur Therapie des fortgeschrittenen… Expand Radium-223 dichloride (Xofigo®; 223Ra) is an alpha-emitting radiopharmaceutical FDA-approved for the treatment of bone metastases… Expand Objectives: Prostate cancer (PC) is the most common cancer in Western countries. Recent advances in the treatment of metastatic… Expand Prostate cancer (PC) is the most common neoplasm in men in Western countries, and approximately 10 – 20 % of patients with PC… Expand Radium-223 dichloride (Xofigo®; formerly Alpharadin™) [hereafter referred to as radium-223] is a first-in-class alpha particle… Expand In patients with advanced castration-resistant prostate cancer (CRPC), symptomatic bone metastases are frequently present. Xofigo… Expand